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Available online 10 March 2014Abstract Human circulating endothelial progenitor cells isolated from peripheral blood generate in culture cells with
features of endothelial cells named late-outgrowth endothelial colony-forming cells (ECFC). In adult blood, ECFC display a
constant quantitative and qualitative decline during life span. Even after expansion, it is difficult to reach the cell dose
required for cell therapy of vascular diseases, thus limiting the clinical use of these cells. Glycosaminoglycans (GAG) are
components from the extracellular matrix (ECM) that are able to interact and potentiate heparin binding growth factor (HBGF)
activities. According to these relevant biological properties of GAG, we designed a GAG mimetic having the capacity to
increase the yield of ECFC production from blood and to improve functionality of their endothelial outgrowth. We demonstrate
that the addition of [OTR4131] mimetic during the isolation process of ECFC from Cord Blood induces a 3 fold increase in the
number of colonies. Moreover, addition of [OTR4131] to cell culture media improves adhesion, proliferation, migration and
self-renewal of ECFC. We provide evidence showing that GAG mimetics may have great interest for cell therapy applied to
vascular regeneration therapy and represent an alternative to exogenous growth factor treatments to optimize potential
therapeutic properties of ECFC.
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704 F. Chevalier et al.Introduction chemokines, cytokines and enzymes (Gallagher, 2006). GAGVascular diseases are the leading causes of death in the world
(Libby et al., 2011; Murray and Lopez, 1997). Current
therapies including life style management, pharmacological
control of risk factors and surgical revascularization do not
completely reverse the pathology. Since the initial discovery
in 1997 of endothelial progenitor cells (EPC) by Asahara et al.
(1997), these cells are considered as a promising therapeutic
tool for vascular repair. Culture of blood mononuclear cells
reveals two distinct populations of EPC that have been
classified according to the time at which they appear in
culture: early endothelial cell colony-forming units (CFU-EC)
and late-outgrowth endothelial colony-forming cells (ECFC),
both expressing specific endothelial markers and with
capabilities to stimulate angiogenesis (Yoder et al., 2007).
On the one hand, CFU-EC differentiate into phagocytic
macrophages and fail to form vessels in vivo. On the other
hand, ECFC display high proliferative potential when com-
pared to mature endothelial cells (Bompais et al., 2004), form
vessels in vivo and are incorporated into pre-existing vascular
networks (Yoder et al., 2007; Au et al., 2008; Sieveking et al.,
2008). Moreover, ECFC are more sensitive to angiogenic
factors, such as VEGF and FGF-2, which confer to these cells
greater protection against cell death. Their functional
features indicate that although these cells have undergone
some differentiation steps, they still have the properties of
immature cells, suggesting greater tissue repair capabilities
(Bompais et al., 2004). However, the use of autologous ECFC
in cell therapy is limited by their rarity in adult peripheral
blood (PB) as they constitute less than 0.01% of circulating
mononuclear cells (Khan et al., 2005; Ingram et al., 2004).
Cord blood (CB) contains more ECFC than PB, and following a
crucial step of adhesion in vitro, it forms primary colonies of
well-circumscribed monolayers of cobblestone appearing
cells. After expansion, ECFC can give rise to secondary
colonies from a single cell (Yoder et al., 2007).
For clinical application, it is important to reach the
therapeutic cell dose with a limited number of cell division
and limited culture time. This will limit occurrence of genetic
abnormalities that may occur during long term cultures as
observed for the use of mesenchymal stem cells (MSC) (Tarte et
al., 2010). To improve production of ECFC, two parameters are
very important: 1) the initial number of colony obtained and 2)
the proliferation rate of endothelial outgrowth obtained
from these colonies. In this study we propose a new strategy
for improving these two parameters, based on the use of
glycosaminoglycan (GAG) type compounds in culture media to
potentiate endothelial cell properties.
Sulfated GAG, such as heparan sulfate (HS) or chondroitin
sulfate (CS), are polysaccharidic molecules associated to a core
protein to form proteoglycans, which interact with proteins to
strengthen the structure and stability of the extracellular
matrix (ECM). GAGalso have functional roles since they regulate
numerous biological processes through their abilities to interact
with heparin-binding growth factors (HBGF) (Gandhi and
Mancera, 2008). The structure of GAG is highly complex due to
heterogeneity in glycosidic linkage, sulfation pattern and
hydrophobic regions regulating their interactionswith surround-
ing molecules. It is now accepted that particular structural
characteristics of GAG are involved in their ability to
modulate the activities of HBGF which include growth factors,thus provide matrix-bound or cell surface-bound reservoirs for
HBGF, protecting them from proteolytic degradation and
increasing their half-life, providing storage and protection
sites (Handel et al., 2005; Friedl et al., 1997). Moreover these
structural features evolve during physiological and pathological
processes and are involved in tissue homeostasis (Huynh et al.,
2012a; Huynh et al., 2012b). According to such interest, a family
of structural and functional analogs of natural GAG has been
developed allowing availability of well-characterized GAG
mimetics (Papy-Garcia et al., 2005). These compounds, also
named RGTA (for ReGeneraTing Agents), greatly increase the
rate and quality of wound healing in various preclinical models
(for review, Barritault and Caruelle, 2006). It was demonstrated
that a RGTA improves in vitro endothelialization of vascular
prosthesis (Desgranges et al., 2001) and partly prevents in vivo
skeletal muscle damage caused by ischemia (Desgranges et al.,
1999). This regenerative effect could be explained by RGTA
resistance to glycanase degradation which improves HBGF
protection and function (Meddahi et al., 2002). It was indeed
demonstrated that RGTA binds VEGF, potentiates its binding to
specific receptors, improves its biological activity onHUVEC and
modulates in vivo angiogenesis (Rouet et al., 2005). Finally,
recent data support the interest of these GAG mimetics
according to their effects on the mobilization and the
potentiation of progenitors and stem cells from hematopoietic
and mesenchymal lineages (Albanese et al., 2009; Frescaline
et al., 2011; Frescaline et al., 2013).
According to the relevance of GAG functions we investi-
gate here whether a selected GAG mimetic [OTR4131] would
be able to potentiate in vitro different properties of human
ECFC from CB, such as adhesion, growth, migration, primary
and secondary colony formation. This should enable optimi-
zation of the expansion capacity of these cells for further
therapeutic applications.
Materials and methods
Materials
The GAG mimetic [OTR4131] was obtained from OTR3 Inc.
(Paris, France). This sulfated dextran derivative, composed
of about 250 glucosidic units, presents degrees of substitu-
tion of carboxylates, and sulfate residues close to heparin,
but differing from this one by a lower acetyl group ratio with
a homogeneous repartition (Papy-Garcia et al., 2005).
Heparin used as natural GAG control was cell culture grade
(Sigma-Aldrich, France, H9399 lot 125K1400). Recombinant
human FGF-2 and human VEGF were purchased from
Promokine (PromoCell, GmbH, Heidelberg, Germany).
Human endothelial progenitor cell isolation
and culture
Human umbilical CB samples were collected in a citrate
phosphate dextrose solution from healthy full-term newborns
after maternal informed consent according to approved
institutional guidelines (Assistance Publique Hôpitaux de
Paris, Paris, France). ECFC were isolated from Cord
Blood MonoNuclear Cells (CBMNC) as previously described
(Vanneaux et al., 2010). To assess an effect of [OTR4131] on
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MV complete media (Lonza, Ermerainville, France) were
divided into 2 equal volumes, in which either phosphate
buffered saline (PBS) or 100 ng/mL of [OTR4131] (final con-
centration) was added. Cell suspensions were both gently
mixed and left for 30 min at room temperature (RT) before
seeding. First media change, following a washing with PBS,
was performed after 24 h to eliminate nonadherent cells and
daily for 7 days. Thereafter, media was then changed every
2 days. ECFC appeared between days 7 and 25 and were
visually identified as well-circumscribed monolayers of
cobblestone appearing cells.
Adhesion assay
ECFC at sub-confluence were trypsinized and incubated in
EGM2-MV complete media supplemented with or without
100 ng/mL of heparin or [OTR4131] for 15 min at RT. Cells
were seeded onto non-coated plates for 2 h at 37 °C and the
amount of attached viable cells was evaluated by a MTS
([3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium], inner salt)-based colori-
metric method (Cory et al., 1991). Briefly, after a washing
step to remove unattached cells, adherent cells were
incubated for 2 h and 30 min at 37 °C with 20% (v:v) MTS
reagent (Promega, Charbonnières, France) in a fresh EBM2
basal medium (without FBS and growth factors). The amount
of soluble formazan product converted from MTS by
dehydrogenase enzymes is directly proportional to the
number of metabolically active cells. The absorbance of
the obtained formazan dye is measured at 492 nm using a
spectrophotometric TECAN Infinite M1000 plate reader
(Tecan, Durham, NC).
Growth factor dependent mitogenic activity assay
ECFC were seeded into 48 well plates at a density of
10,000 cells/cm2 and left for 5 h in complete EGM2-MV
medium to allow cell adhesion. To investigate the effect of
GAG on growth factor-induced proliferation, medium was
changed by an EBM2 basal medium supplemented with 0.5%
FBS and SingleQuots of growth factors devoid of FGF-2 and
VEGF (EGM2 modified medium–0.5% FBS). After overnight
incubation, medium was replaced by the same medium
supplemented with FGF-2 or VEGF. GAG, [OTR4131] or
heparin, was added to wells from 0.1 to 100 μg/mL (final
concentration). Cells were incubated for 5 days, with a
renewal of medium, GAG and growth factors at day 3. The
amount of viable cells was evaluated by a MTS-based
colorimetric method as previously described.
Chemotactic migration assay
ECFC migration in response to VEGF gradient was assessed in
a 24-well modified Boyden chamber, on polycarbonate
membrane filter with 8 μm pore diameter (BD Biosciences)
coated with 50 μg/mL rat tail collagen type I (BD Biosci-
ences). After an overnight starvation in EBM2 basal medium
supplemented with 0.2% FBS, ECFC were loaded in starving
medium into the upper part of the microchamber at 200,000
cells/well, with the same medium containing or not 2 ng/mLof VEGF with or without 1 μg/mL of [OTR4131] or heparin on
the lower chambers. After 12 h of incubation cells on the
upper surface of the membrane filter were removed by wiping
with a cotton swab. Then, all membranes were MGG-stained,
mounted and photographed through an Aristoplan Leitz
microscope coupled to a CoolSnap color CCD camera (Photo-
metrics). The number of cells per field was automatically
counted using a previously described procedure (Destouches et
al., 2012) programmed with the macro language of the ImageJ
software (Rasband, 1997–2013). Briefly, the red component of
RGB images was extracted and segmented using the so called
“Otsu” method, and then subsegmented with an 8-bit
watershed method. Object count was then automatically
performed to get the cell number. Results are reported as the
mean of 18 areas from three pictures by filter, in duplicate
during 3 independent experiments.
Clonogenicity frequency
Serial dilutions of ECFC were performed to obtain 32, 16, 8,
4, 2, 1 and 0.5 cells per well — with 12 to 36 replicate wells
per cell dilution. Cells were maintained in EGM2-MV
complete medium supplemented or not with 1 μg/mL of
[OTR4131] or heparin (final concentration). Each medium was
renewed every 3 days. Individual wells were scored for the
presence of colony after 15 days of culture. The percentage
of negative wells as a function of the number of cells/well
overlaid was used to estimate the frequency of the
clonogenicity, as the 37% log intercept according to Poisson
statistics.
Flow cytometry
Fluorescence activated flow cytometry was performed with BD
Accuri C6 flow cytometer (BD) and a minimum of 10,000 events
were analyzed for each sample. The cells were harvested,
washed in BSA 0.5% in PBS and incubated for 45 min at 4 °C,
with primary antibodies to analyze the expression of endothe-
lial cell surface marker proteins: FITC-conjugated mouse
anti-human CD31 (PECAM-1) IgG1 (BD), PE-conjugated mouse
anti-human CD144 IgG1 (Beckman Coulter, France) and Alexa
Fluor 647-conjugated mouse anti-human CD309 (VEGFR2) IgG1
(BD). All the antibodies were used in the concentrations
suggested by the suppliers. Living cells were discriminated by
adding the 7AAD dye (BD). Background fluorescence was
obtained from the negative control cells stained with
FITC-conjugated mouse IgG1, PE-conjugated mouse IgG1 and
APC-conjugated mouse IgG1 antibodies (Beckman Coulter) and
subtracted from the mean channel fluorescence of the specific
staining patterns. The expression of each antigen was
expressed as the mean channel fluorescence.
Endothelial function assays
The ability to express adhesionmolecules ICAM-1 and VCAM-1 in
inflammatory conditions and the ability to uptake acetylated
LDL are two main endothelial functional assays. In order to
explore these functional capacities, ECFC were cultured with
either 10 ng/mL of TNFα (R&D Systems, France) for 18 h orwith
15 μg/mL of Ac-LDL Alexa Fluor 488 (Life technologies, Cergy
Pontoise, France) for 4 h at 37 °C. Expression of ICAM-1 and
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and internalization of Ac-LDL was visualized using a fluorescent
microscope, as previously described (Lavergne et al., 2012).
The number of Ac-LDL positive cell was measured by manual
counting under a fluorescent microscope.
Immunocytochemistry
ECFC were fixed in 4% paraformaldehyde for 10 min and
washed in PBS–BSA 0.5%. Saturation and permeabilization
were performed by incubating fixed cells in PBS–FCS 2%–
Triton 0.1% solution for 1 h at RT. After washing steps,
staining of specific endothelial cell markers was performed
using mouse anti-human CD31 (BD) and rabbit anti-human von
Willebrand Factor (vWF; Dako, Trappes, France) primary
antibodies followed by Alexa Fluor 488-conjugated goat
anti-mouse and Alexa Fluor 647-conjugated goat anti-rabbit
secondary antibody (Life Technologies) staining. Negative
control samples included cells treated with secondary
antibodies only. All the antibodies were used in the
concentrations suggested by the suppliers. Nuclei were
counterstained with 4′,6′-diamidino-2-phenylindole (DAPI;
Sigma-Aldrich). Images were visualized using an Olympus
BX60 microscope (Olympus Optical, Hamburg, Germany),
digitalized using a CCD camera (Photometrics CoolSNAP fx;
Roper Scientific, Tucson, AZ) and analyzed using MetaView
image analysis system (Universal Imaging, Downingtown, PA).
Endothelial tube formation in MatrigelTM in vitro
Ability of ECFC to organize into capillary-like structures in the
presence of basement membrane matrix was analyzed using
Matrigel™ (BD, France) as previously described (Lavergne et al.,
2012). To assess the pro-angiogenic effect of GAG, ECFC
were cultured on Matrigel™ with complete EGM2-MV medium
supplemented or notwith 1 μg/mL of [OTR4131] or heparin (final
concentration). Four pictures per well were taken using a
camera associated to an inverted microscope with a 4×
objective in phase contrast mode. Images were analyzed using
an original home-made plugin (Carpentier et al., 2012),
developed for the ImageJ software (Carpentier, 2012). Briefly,
phase contrast images were segmented and skeletonized. The
trees were then analyzed by detection of junctions and
extremities, defining the segments and branches of the cellular
meshed network organization.
In vivo MatrigelTM plug assay
Eight week old female NOD/SCID mice (Janvier, CERJ, Laval,
France) were injected subcutaneously into inner flank region
with 0.5 mL of MatrigelTM containing both 750,000 ECFC and
250,000 human bone marrow mesenchymal stem cells (MSC,
ABCell-Bio, Paris, France) with or without [OTR4131] (1 or
10 μg/mL final concentration). The injected MatrigelTM
rapidly formed a single solid gel plug. After 7 days, the
mouse skins were pulled back to expose the plugs which
were then dissected. The intact plugs were frozen in
isopentane precooled in liquid nitrogen. Sections of 8 μm
thickness were cut using a cryostat, fixed with a 4% parafor-
maldehyde solution for 10 min at RT, and stained with specific
antibodies to detect human ECFC into the plugs. Cellpermeabilization was performed by incubating fixed sections
in PBS–Triton 0.1% solution for 10 min at RT, and saturation in
PBS–goat serum 5% solution for 1 h at RT. After washing steps,
staining of specific endothelial cell markers was performed
using mouse anti-human CD31 (BD) and rabbit anti-human von
Willebrand Factor (Dako) primary antibodies followed by Alexa
Fluor 488-conjugated goat anti-mouse and Alexa Fluor
647-conjugated goat anti-rabbit secondary antibody (Life
Technologies) staining. Nuclei were counterstained with DAPI.
Images were visualized using an Olympus BX60 microscope
(Olympus Optical, Hamburg, Germany), digitalized using a CCD
camera (Photometrics CoolSNAP fx; Roper Scientific, Tucson,
AZ) and analyzed using MetaView image analysis system
(Universal Imaging, Downingtown, PA). This experiment was
repeated twice, and included 3 groups of 4 mice: ECFC + MSC
without GAG, ECFC + MSC + GAG at a concentration of 1 μg/mL
and ECFC + MSC + GAG at a concentration of 10 μg/mL.
Statistical analysis
Each experiment was performed at least three times and
each sample was tested in triplicate. Data are expressed as
mean ± SEM. Statistically significant difference was deter-
mined with one way ANOVA analysis followed by the Dunnett
post-test when there were more than two groups. For
analysis between two groups Student's-t test was used.
Results
[OTR4131] improves colony forming efficiency of
human ECFC
The colony forming efficiency (CFE) of ECFC is a very critical
step in production of therapeutic endothelial cells, as it will
determine the first pool of endothelial outgrowth from which
further expansion steps will proceed. The capacity of the
[OTR4131] mimetic to improve this step was evaluated on ECFC
from human CBMNC (Fig. 1). A single 24 h exposure of cells to a
dose of 100 ng/mL of [OTR4131] added in EGM2-MV medium at
day 0 is associated to a significant 1.8-fold increase of the CFE as
compared to PBS-treated cells (Fig. 1A). A continuous exposure
to 100 ng/mL of [OTR4131] during the first 7 days of culture,
corresponding to the daily renewing medium needed to obtain
ECFC, significantly increases by 2.7-fold the CFE compared to
the PBS-treated group (Fig. 1B), with larger colony size
corresponding to an increased number of cells per colony
(data not shown). Same results were obtained with 1 μg/mL
dose of [OTR4131] (data not shown). These data clearly indicate
that [OTR4131] is able to increase the number of ECFC obtained
from a fixed cord blood (CB) volume. Moreover this could be due
to [OTR4131] effects not only on early steps such as adhesion of
ECFC but also on later steps such as self-renewing and/or
proliferation of ECFC.
Phenotype and functionality of ECFC isolated with
[OTR4131]
Characterization of ECFC populations obtained in [OTR4131]-
supplemented culture conditions was performed in single shot
or 7 day continuous additions by flow cytometry (Fig. 2A) and
Figure 1 Effect of [OTR4131] on human ECFC colony formation efficiency. Number of ECFC colonies, identified as
well-circumscribed monolayers of cobblestone appearing cells by visual inspection, were counted after 25 days of culture of
purified CBMNC fraction, divided into 2 equal volumes and incubated either in PBS or [OTR4131] solutions, for 24 h (panel A) or 7 days
(panel B). Values are the mean and SEM calculated from either 6 (24 h) or 9 (7 days) individual blood samples processed in
independent experiments (n = 6 or n = 9, *p b 0.05; **p b 0.01).
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isolated with 7 day continuous additions of [OTR4131] and
further amplified in medium without GAG express cell surface
endothelial markers, including PECAM-1 (CD31), VE-Cadherin
(CD144), VEGF-R2 (CD309) and vWF to the same extent than
cells isolated and cultured without [OTR4131]. Moreover,
Tumor Necrosis Factor alpha (TNF-alpha) activation (Fig. 2C)
and acetylated low density lipoprotein (LDL-Ac) uptake
(Fig. 2D) assays indicated that ECFC isolated in the presence
of [OTR4131] are fully functional, since they are able to uptake
in comparable extent LDL-Ac through specific receptor
(PBS-treated positive cells: 94.9% ± 1.2, [OTR4131]-treated
positive cells: 97.8% ± 1.2), and can be activated through
TNF-alpha-pathways as efficiently as observed for classically
isolated cells without [OTR4131]. Same results were obtained
from ECFC treated by single shot of [OTR4131] (data not
shown). Finally the two kinds of isolation procedures lead to
the production of ECFC able to form a vascular-like network
on MatrigelTM (Fig. 2E).
Effect of [OTR4131] on adhesion of ECFC
Because cell adhesion is a crucial property involved in CFE of
ECFC, we explored the effect of [OTR4131] in this process.
Since data collected from ECFC are limited by the small
number of cells in colonies at passage 0, we analyzed the
effect of pre-incubating [OTR4131] with ECFC on their
capacities to attach to culture dish with cells at P3. In
contrast to heparin, a natural GAG used as control, which
inhibited adhesion by 15%, the [OTR4131] compound signifi-
cantly improved ECFC adhesion by 25% (Fig. 3).
[OTR4131] potentiates heparin binding growth factor
effects on ECFC proliferation
To further explore the effect of GAG mimetic and because
data collected from ECFC are limited by the low number of
cells at passage 0, we tested the effect of GAG on ECFC at P2
induced to proliferate for 5 days. First experiments were
performed with addition of both GAG, natural or mimetic, in
EGM2-MV complete medium and no effect was observed(data not shown), probably due to a saturation of mitogenic
signals in this complete medium. In order to measure a
possible effect of GAG on ECFC growth, we used modified
EGM2-MV medium with only 0.5% of FBS (0.5% EGM2-MV) in
which we controlled the concentration of VEGF and FGF-2,
the two most potent cytokines for ECFC proliferation.
Figs. 4A and B show results of VEGF and FGF-2 dose-effect,
respectively on proliferation rate of ECFC in 0.5% EGM2-MV
for 5 days as compared to medium without neither FGF-2 nor
VEGF. We confirm that an ECFC proliferation rate increases
according to increasing dose of the growth factor added in
the medium and reaches saturation levels of 2 ng/mL and
10 ng/mL for FGF-2 and VEGF respectively. We clearly
observed that suboptimal concentration of both growth
factors is around 1 ng/mL and decided to use this dose
to test potential synergic effect of heparin and [OTR4131]
(Figs. 4C, D).
ECFC proliferation rate in 0.5% EGM2-MV critically de-
creased when compared to EGM2-MV complete medium
(7 fold). Addition of increasing doses of GAG in 0.5%
EGM2-MV did not affect the ECFC growth (data not shown),
suggesting that GAG do not promote proliferation properties
of other growth factors present in the medium (neither IGF-1
nor EGF) or secreted by ECFC. Whereas addition of the
suboptimal dose of 1 ng/mL VEGF alone didn't have signifi-
cant effect, addition of 1 ng/mL FGF-2 alone increased 1.7
fold the proliferation rate of ECFC (Figs. 4C, D). In the case of
proliferation associated to VEGF, whereas heparin signifi-
cantly decreased the proliferation rate of ECFC at high doses,
the mimetic [OTR4131] induced a significant 1.35 fold increase
of ECFC proliferation, only at 0.1 μg/mL. In the case of ECFC
proliferation induced by 1 ng/ml of FGF-2, a growth effect
was observed with addition of 0.1 μg/mL of heparin (1.4-fold
increase) but which decreased with higher doses. A lower
increase of ECFC proliferation rate was obtained with
0.1 μg/mL of [OTR4131], but the FGF-2-induced prolifera-
tion was significantly potentiated in a dose-dependent
manner since at higher doses of 1 μg/mL and 10 μg/mL,
increases of 1.4-fold and 1.8-fold respectively were
observed. These data clearly indicate that [OTR4131] is
able to potentiate HBGF activity on ECFC proliferation in
low serum condition.
Figure 2 Phenotype and functionality of human ECFC isolated with [OTR4131]. Phenotypical considerations: (A) Flow cytometry
analysis of the expression of specific endothelial markers CD31, CD144 and CD309 (IgG: black line; expression: red line; MFI: Mean
Fluorescence Intensity in arbitrary unit). (B) ICC analysis of specific endothelial markers CD31 (red color) and vWF (green color)
associated to nuclei staining (blue color); scale bar = 100 μm. Functional considerations: (C) Flow cytometry analysis of ICAM-1 and
VCAM-1 surexpression according to TNF alpha activation (IgG: black line; basal expression: red line; surexpression: blue line). (D) LDL-Ac
(green color) uptake associated to nuclei staining (blue color); scale bar = 100 μm. (E) Tubular network formation on Matrigel™.
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give rise to a clonal progeny
ECFC derived from EPC retain some immature properties
after adhesion and proliferation in vitro such as the ability to
form secondary colonies from a single cell. In order to
evaluate this secondary colony forming capacity of ECFC, we
adapted a serial dilution protocol, as described for hemato-
poietic stem cells for the quantification of cobblestone
area-forming cells (Pettengell et al., 1994). This method
permits evaluation of the influence of GAG on ECFC self-
renewal capacity. In the absence of GAG, ECFC secondary
colony frequency ranged between 1/2 and 1/40. According
to this inter-individual variability, and to be able to comparethe frequency obtained in the presence of GAG, we defined
a clonogenicity index which corresponds to the ratio of the
frequency with/without GAG. Thereby, while heparin had no
significant effect with a colony forming index at 1.3,
[OTR4131] increased the colony forming index by 2-fold
(Fig. 5).
[OTR4131] improves migration of ECFC
GAG mimetic effect was tested in vitro on ECFC migration in
Boyden chambers using VEGF as chemoattractant and com-
pared to heparin (Fig. 6). A basal migration level was defined
in EBM2 basal medium with 0.2% serum in the absence of both
VEGF and GAG (dotted line) and was enumerated around 100
Figure 5 Effect of heparin and [OTR4131] on human ECFC
secondary clonogenicity. Clonogenicity index (Frequency with
GAG / Frequency CT) of ECFC after 15 days of culture with or
without 1 μg/mL final concentration of heparin or [OTR4131].
Values are the mean and SEM calculated from 6 individual blood
samples in 6 independent experiments (n = 6, *p b 0.05).
Figure 3 Effect of heparin and [OTR4131] on human ECFC
adhesion. Relative adhesion capacity of ECFC pre-incubated
with or without 100 ng/mL heparin or [OTR4131]. The relative
adhesion performance of each condition was expressed as fold
changes as compared to the control condition without GAG
(PBS). Values are the mean and SEM calculated from triplicates
in 4 independent experiments (n = 4, *p b 0.05; ***p b 0.001).
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[OTR4131] alone to basal medium (0.2% serum) induced a 2-fold
increase of ECFC migration. This increase was similar to that
induced by addition of VEGF (2 ng/mL). This suggests thatA
B
C
D
suboptimal dose
suboptimal dose
Figure 4 Effect of heparin and [OTR4131] on human ECFC proliferat
either FGF-2 (panel A) or VEGF (panel B) and amplified with 1 ng
concentration of [OTR4131] or heparin in EGM2 modified medium–0.
expressed as fold changes as compared to condition without cytokine
the dotted line represents the proliferation rate with cytokine alon
independent experiments (n = 4, *p b 0.05; **p b 0.01; ***p b 0.001heparin and [OTR4131] are able to potentiate chemoattraction
of ECFC mediated by growth factors present in the 0.2% serum
medium. Finally, in the presence of VEGF, addition of heparin
or [OTR4131] statistically improves the migration rate by 1.5ion. Proliferation rate of ECFC with increasing concentrations of
/mL of FGF-2 (panel C) or VEGF (panel D) with the indicated
5% FBS for 5 days. The proliferation rate of each condition was
s and without GAG (=1). In order to see the effect of GAG alone,
e. Values are the mean and SEM calculated from triplicates in 4
).
Figure 6 Effect of heparin and [OTR4131] on human ECFC migration capacity. (A) Representative pictures of MGG-stained transwell
membranes. (B) Migration levels of ECFC exposed to 1 μg/mL of heparin or [OTR4131] with or without VEGF. Data represent the mean
and SEM from 3 independent experiments with each condition in duplicate (each value was determined by the mean of three different
representative photographs) (n = 3, *p b 0.05; **p b 0.01; ***p b 0.001).
710 F. Chevalier et al.fold and 2 fold, respectively, reaching similar level obtained
with 10 ng/mL of VEGF in the absence of GAG. This clearly
indicates that [OTR4131] and heparin are able to potentiate
chemoattractant effect of VEGF.
[OTR4131] does not modify vascular-like structure
formation on MatrigelTM in vitro or in vivo
In vitro MatrigelTM assay allows investigating a functional
ability of ECFC to form vascular-like tubes on a pro-angiogenic
substrate. As shown in Figs. 7A and B, ECFC cultured in the
presence of 1 μg/mL of [OTR4131] displayed a similar capacity
to form tubes on MatrigelTM as control ECFC. Interestingly,
1 μg/mL of heparin induces a better network of vascular-like
structures including 40% more segments, nodes and mesh with
a total length of the network 20% higher. In vivo MatrigelTM
implantation experiments permit to evaluate the capacity of
[OTR4131] to improve ECFC-induced angiogenesis in thepresence of MSC used as supportive cells. As for the in vitro
assay, the presence of 1 μg/mL (Fig. 7C) or 10 μg/mL (data
not shown) of [OTR4131] GAG mimetic does not induce
significant differences in the formation of vascular structures
as compared to control plugs with same number of cells but
without GAG.
Discussion
EPC are considered as a promising cell therapy tool for ischemic
disease, but these cells represent a scarce population in blood
and furthermore, many studies on circulating cell populations
expressing combination of CD133, KDR and CD34 markers
demonstrate that an inverse correlation exists between risk
factors for cardiovascular diseases and potential EPC number
and functionality (for review: Alaiti et al., 2010), suggesting
that ECFC could be affected too. This is reinforced by recent
published data of Shelley et al. (2012) demonstrating that the
711Glycosaminoglycan mimetic improves enrichment and cell functions of human endothelial progenitor cell coloniesnumber and functionality of ECFC are affected in aged
individuals, which represent the population with highest
cardiovascular risk. To further improve the efficacy of EPC
transplantation, several approaches are currently being devel-
oped to enhance EPC expansion and bioactivities. These are
mainly based on the combination of several growth factors such
as SCF, FGF-2, VEGF, TPO, GCSF, and IL-3 and 6 in culture
media (Schlechta et al., 2010; Janic et al., 2010; Kalka et al.,
2000; Lippross et al., 2011; O. E. et al., 2011; Senegaglia et al.,
2010). Most of them are heparin-binding cytokines. Neverthe-
less, despite progress in growth factor combination needed for
endothelial system, the optimal expansion conditions compat-
ible with clinical use in serum-free medium still need to be
defined. Since GAG are polysaccharide components of the ECM,
known to potentiate the bioactivity of numerous HBGF on cells,
we hypothesize that they will potentiate the activity of
exogenous growth factors added to culture medium and/or
secreted by the cells. However, GAG mixtures from natural
origin are not structurally well characterized and carry high risk
of contamination avoiding their clinical use for therapeutic
application. Here, we studied the effect of a syntheticFigure 7 Effect of GAG on human ECFC tube formation. (A) Repres
formed by ECFC in vitro in the presence or not of 1 μg/mL of hepari
networks identifying segments (yellow color), mesh (blue color) and n
formation. Values are the mean and SEM calculated from triplicat
***p b 0.001). (C) Representative in vivo Matrigel™ plug sections lab
anti-human specific CD31 antibody (green) with DAPI staining (blue) t
d). Cells were implanted alone (a and b) or with 1 μg/mL of [OTR413GAG-like product, the [OTR4131] compound, synthesized in
reproducible and standardized methods (Papy-Garcia et al.,
2005) compatible with clinical use, on the properties of ECFC.[OTR4131] optimizes the essential steps of in vitro
ECFC colony formation frequency
Most patients with vascular diseases, eligible for autologous
ECFC cell therapy are aged and display decreased frequency
of these progenitor cells. Use of allogenic ECFC from CB may
represent an efficient alternative strategy. To access
existing CB banks, because the freezing conditions are not
adapted to EPC and yield lesser number of ECFC (Vanneaux
et al., 2010), the ECFC production from frozen CB units must
be optimized. Thus, whatever the source of blood selected
for obtaining ECFC, improvement of the number of colonies
is an important issue for further reaching the cellular
therapeutic dose. We demonstrate here that addition of a
GAG mimetic during the first 24 h of CBMNC plating results in
a 2 fold increase of the number of ECFC colonies (Fig. 1A).entative phase contrast pictures of tubular network on Matrigel™
n or [OTR4131] and corresponding extracted skeletons of tubular
odes (red color). (B) ImageJ plugin analyzed parameters of tube
es in 3 independent experiments (n = 3, *p b 0.05; **p b 0.01;
eled with an anti-von Willebrand Factor antibody (red) and an
o detect human ECFC, magnification ×25 (a and c) or ×63 (b and
1] (c and d).
Figure 7 (continued).
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mimetic at this very early step of colony formation is the
improvement of adhesion properties of EPC. This hypoth-
esis is supported by the ability of the same GAG mimetic
to improve cell adhesion of ECFC (Fig. 3). This result is
very promising since it proves that we are able to
optimize the essential step of in vitro ECFC colony
formation. This is reinforced by previous similar data
demonstrating that treatment of rat bone marrow mono-
nuclear cells with GAG mimetics during the first step of
culture increases the colony forming efficiency of MSC
(Frescaline et al., 2011).
Furthermore, addition of the [OTR4131] mimetic not only
for the first 24 h after plating but also all along the first
7 days of culture improves almost 3 fold the number of
colonies (Fig. 1B). These data clearly suggest that the GAG
mimetic acts not only on early steps of colony formation but
also on later steps such as self-renewal and/or cell prolifer-
ation of ECFC. This hypothesis is supported by our results
demonstrating an improving effect of this GAG mimetic
on ECFC proliferation and secondary colony frequency
(Figs. 4 and 5). In the past few years, evidences about the
regulation of stem cell behavior by ubiquitous GAG such HS
and CS have been accumulated. In mouse embryonic stem
cell, siRNA knockdown of the EXT1 gene, encoding the
enzyme involved in the elongation of the HS chains, leads to
a decrease by half of the number of colonies remaining
undifferentiated, even in the presence of LIF and serum, and
to a critical decrease of the proliferation rate (Sasaki et al.,
2008). CS is also involved in stem cell fate as demonstrated by
its involvement in the regulation of signaling pathways
essential for the proliferation, self-renewal, and cell lineage
commitment of neural stem/progenitor cells (Purushothaman
et al., 2012). All these studies clearly highlight the impor-
tance of HS and CS in the modulation of stem cell self-renewaland lineage fate (Kraushaar et al., 2013; Smith et al., 2011).
Our data clearly demonstrate for the first time that [OTR4131]
GAG mimetic, by acting on ECFC clonogenicity, is able to
impact stem cell properties as it was demonstrated for
natural GAG.[OTR4131] is able to potentiate the in vitro
amplification of ECFC
GAG are essential for HBGF signaling implicated in endothe-
lial cell proliferation since it has been shown that heparin
potentiates mitogenic effect of both FGF-1 and VEGF165 on
endothelial cell (Thornton et al., 1983; Ono et al., 1999;
Ashikari-Hada et al., 2005) and HS is required for binding
FGF-2 and VEGF165 to their high affinity receptors (Yayon
et al., 1991; Gitay-Goren et al., 1992). We show here that
[OTR4131] mimetic is able to potentiate ECFC proliferation
induced by VEGF and FGF-2, in a cell culture medium with a
low (0.5%) concentration of serum (Fig. 4). Interestingly, our
data also indicate that the [OTR4131] GAG mimetic action is
much higher on FGF-2 effect than on VEGF. This is probably
due to different affinities of this GAG toward each growth
factor. This hypothesis is supported by several studies
analyzing GAG structure relationships with specific binding
affinity and different biological effects of HBGF (Ashikari-
Hada et al., 2005; Cole et al., 2010; Goger et al., 2002;
Ouidja et al., 2007; Zhao et al., 2012). Moreover, our data
are in accordance with previously published results demon-
strating that another GAG mimetic [OTR4120] binds to
VEGF165 and potentiates the affinity for its receptors,
leading to better in vitro VEGF-induced proliferation and
migration of endothelial cells such as HUVEC (Rouet et al.,
2005). Otherwise, we had already observed that only
[OTR4131] significantly potentiates the growth of rat MSC
713Glycosaminoglycan mimetic improves enrichment and cell functions of human endothelial progenitor cell coloniesthrough a FGF-2/FGFR1 pathway, when compared to
[OTR4120] or heparin (Frescaline et al., 2011).
[OTR4131] promotes the migration of ECFC
In this study, we show that [OTR4131] is able to promote the
VEGF-dependent migration of ECFC (Fig. 6). Moreover, in the
absence of VEGF it also potentiates migration, probably
through interaction with different chemo-attractant mole-
cules secreted by cells or present in the medium. Likewise,
we previously demonstrated that [OTR4131] is able to
potentiate the migration of rat MSC (Frescaline et al.,
2011). In addition, [OTR4131] is able to mobilize immature
population of hematopoietic stem cells according to a
process that involves SDF-1 interactions (Albanese et al.,
2009). These observations are supported by the demonstra-
tion that some HS carrying acetyl groups, like [OTR4131] GAG
mimetic, display a better binding of chemokines such CCR2
(MCP-1) (Schenauer et al., 2007) which is involved in EPC
homing to a neovascularization site (Hristov et al., 2007).
Finally, such migratory effect of [OTR4131] suggests that this
GAG mimetic could be of great interest if injected during a
regenerative process, to attract therapeutic stem cells and
mobilize endogenous circulating or resident ones into the
injury site.
Role of [OTR4131] in angiogenesis
We demonstrate that the [OTR4131] mimetic doesn't improve
significantly ECFC angiogenic capacity on Matrigel™ neither in
vitro nor in vivo (Fig. 7). However, it has been documented
that other GAG mimetics with structure close to that of
[OTR4131], are able to potentiate angiogenesis in vivo in
chicken embryo chorioallantoic membrane development
(Rouet et al., 2005) or in pig model of myocardial ischemia
(Yamauchi et al., 2000). Our hypothesis is that such GAG
mimetics potentiate angiogenesis by reinforcing and stabiliz-
ing damaged extracellular matrix during tissue remodeling
that occurs for example during embryonic development or in
the regeneration process following injury. Moreover, GAG
mimetics may also enforce the action of heparin binding
growth factor, which may be present at limited concentration
in the injured tissues. In Matrigel™ experiments, there is no
tissue remodeling, and thus, the GAG mimetics' role in
replacement of degraded endogenous GAG is not required.
Moreover, growth factors (VEGF, FGF-2) are present at high
concentrations, and potentialization of their action by GAG
mimetics is not needed. Indeed, in our in vitro experiments,
we had to adapt significantly culture conditions in order to
make apparent GAG mimetic effects on ECFC (low serum
concentration and growth factors at minimal concentrations),
whereas in the in vivo Matrigel™ assay such flexibility in the
experimental conditions is difficult to obtain. Moreover, we
demonstrate here that [OTR4131] is able to reinforce cell
adhesion in vitro whereas heparin inhibits it. However, it is
well known that partial disruption of endothelial cell–matrix
contact is a pre-requisite for triggering angiogenesis (Ingber,
2002), suggesting that such anti-adhesive effect of heparin
could explain GAG-stimulated angiogenesis in Matrigel™ in
vitro. Thus, the Matrigel™ model does not fully represent an
in vivo situation in which GAG mimetic effects could beevidenced. The putative synergy between ECFC and GAG
mimetics, especially the [OTR4131] compound for inducing
vascularization in vivo remains to be demonstrated in a more
physiological model of angiogenesis.Conclusion
Our results demonstrate that the GAG mimetic [OTR4131] is
able to enhance the critical human ECFC colony formation
frequency, required to improve the amplification of ECFC,
and to promote cell properties such as cell adhesion,
migration and self-renewal. Moreover, [OTR4131] is able to
potentiate the mitogenic effect of angiogenic growth factors
such as FGF-2 and VEGF in low serum condition. Considering
cell therapy for ischemic diseases by ECFC isolated from CB
or PB, [OTR4131] appears to be a promising tool to increase
the cell recovery from these blood sources without modify-
ing their properties and to optimize the development of
clinical grade serum-free medium. Moreover, these data
suggest that matrix therapeutic strategy based on GAG
mimetics will be in accordance with innovative tissue
engineering approaches to synergize exogenous growth
factor treatments and/or to potentiate in vivo effects of
cell-based therapeutic products. The addition of [OTR4131]
to injured tissue should constitute scaffolds for a proper
micro-environment before cell transplantation that will be
able, according to its migratory effect, to induce the in situ
recruitment of stem/progenitor cells to the defective sites
and increase again tissue repair.Acknowledgments
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